10-Q: Mustang Bio Narrows Losses, Boosts Cash Amid Strategic Shift

Mustang Bio, a clinical-stage biopharmaceutical company, reported significantly reduced net losses and increased cash reserves for the first half of 2025, driven by strategic cost-cutting measures and recent capital raises, though substantial doubt about its going concern status persists.

Summary

• Mustang Bio is a clinical-stage biopharmaceutical company focused on CAR T and oncolytic virus therapies for cancers and autoimmune diseases, operating as a majority-controlled subsidiary of Fortress Biotech, Inc.
• The company reported a net loss of $0.76 million for the three months ended June 30, 2025, a significant improvement from a $8.20 million net loss in the same period of 2024.
• For the six months ended June 30, 2025, the net loss was $0.92 million, substantially lower than the $13.39 million loss in the prior year period.
• Cash and cash equivalents increased to $12.66 million as of June 30, 2025, up from $6.84 million at December 31, 2024.
• Total stockholders' equity shifted from a deficit of $3.87 million at December 31, 2024, to a positive $2.89 million at June 30, 2025.
• Research and development expenses decreased significantly, showing a credit of $0.87 million for the six months ended June 30, 2025, compared to an expense of $8.16 million in the prior year, primarily due to workforce reduction, clinical trial closures, and termination of the uBriGene transaction.
• General and administrative expenses also decreased to $2.00 million for the six months ended June 30, 2025, from $2.96 million in the prior year.
• The company successfully raised approximately $6.8 million in net proceeds from a February 2025 equity offering and an additional $0.6 million from an At-the-Market (ATM) offering during the first half of 2025.
• Subsequent to the quarter, in July 2025, the company received approximately $7.1 million from warrant exercises, issuing about 2.9 million shares.
• Despite financial improvements, management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least 12 months from the financial statement issuance date, necessitating additional capital.
• The company terminated its Plantation Street Facility lease in February 2025, moving its headquarters to Fortress-leased office space, and sold remaining equipment to preserve capital.
• Product candidates MB-101 and MB-108 received Orphan Drug Designation from the FDA for malignant glioma and astrocytomas/glioblastoma, respectively.
• MB-106 (CD20-targeted CAR T cell therapy) received Regenerative Medicine Advanced Therapy (RMAT) designation for Waldenstrom macroglobulinemia and follicular lymphoma.

Sentiment

Score: 4

Explanation: While the company has significantly reduced its net losses and increased its cash position through recent financings and aggressive cost-cutting, the explicit 'going concern' warning and continued reliance on future capital raises for its early-stage pipeline indicate a high-risk profile. The strategic shifts and delays in company-sponsored trials, while necessary for capital preservation, also reflect ongoing challenges. The positive clinical designations are promising but do not offset the immediate financial uncertainties.

Positives

• Net loss significantly reduced to $0.76 million for Q2 2025 from $8.20 million in Q2 2024, and to $0.92 million for H1 2025 from $13.39 million in H1 2024, indicating improved cost control.
• Cash and cash equivalents increased to $12.66 million as of June 30, 2025, from $6.84 million at December 31, 2024, strengthening liquidity.
• Stockholders' equity turned positive to $2.89 million from a deficit of $3.87 million, reflecting successful capital raises and reduced losses.
• Research and development expenses saw a substantial decrease, including a credit of $0.87 million for H1 2025, due to strategic cost-cutting measures like workforce reduction and facility closure.
• Successful capital raises in February 2025 ($6.8 million net) and through ATM offering ($0.6 million gross), with an additional $7.1 million from warrant exercises in July 2025, providing crucial funding.
• Orphan Drug Designations granted by the FDA for MB-108 (malignant glioma) and MB-101 (recurrent diffuse and anaplastic astrocytoma and glioblastoma), offering incentives and potential market exclusivity.
• Regenerative Medicine Advanced Therapy (RMAT) designation for MB-106 in Waldenstrom macroglobulinemia and follicular lymphoma, potentially expediting development and review.

Negatives

• The company has incurred significant losses since inception, with an accumulated deficit of $397.6 million as of June 30, 2025.
• There is substantial doubt regarding the company's ability to continue as a going concern for the next 12 months, necessitating additional financing.
• No revenue has been generated from development-stage products, and profitability is not expected in the foreseeable future.
• The company's short operating history makes it difficult to evaluate long-term business prospects and ability to commercialize products.
• Reliance on third parties for preclinical studies, clinical trials, and manufacturing introduces risks of unsatisfactory performance or delays.
• The company is subject to 'baby shelf rules' limiting the amount of funds that can be raised through primary public offerings to one-third of its public float, as its public float is less than $75 million.

Risks

• Incurrence of significant and continued losses, with no expectation of profitability in the foreseeable future.
• Substantial doubt regarding the ability to continue as a going concern, requiring additional financing that may not be available on acceptable terms.
• Future capital raising activities may dilute current stockholders, restrict operations, or force relinquishment of proprietary rights.
• Short operating history makes it difficult to evaluate business and prospects, with no demonstrated ability to successfully complete clinical trials or obtain regulatory approvals.
• Future growth and success are highly dependent on the successful development and commercialization of unproven CAR T and oncolytic virus product candidates.
• Preclinical and clinical development are highly speculative and carry high failure risk, with no guarantee of regulatory approvals on projected timelines, if at all.
• Product candidates may demonstrate adverse side effects, leading to abandonment or limitation of development.
• Even if approved, products may be subject to post-marketing requirements and increased regulatory scrutiny.
• Competitors may develop treatments for target indications, limiting commercial opportunity and profitability.
• If approved products are not broadly accepted by the healthcare community, revenues will likely be limited.
• Potential for substantial product liability claims, which may exceed insurance coverage.
• Reliance on third parties for preclinical studies, clinical trials, and manufacturing, with risks of unsatisfactory performance or failure to meet deadlines.
• Reliance on clinical data and results obtained by third parties, which may prove inaccurate or unreliable.
• Need to license certain intellectual property from third parties, which may not be available or on commercially reasonable terms.
• Operating in a heavily regulated industry, with potential for increased compliance costs and adverse impacts from future legislation or administrative actions.
• Subject to anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare laws and regulations, risking criminal sanctions or civil penalties.
• Exposure to environmental, health, and safety laws and regulations, potentially leading to fines or penalties.
• Inability to obtain and maintain sufficient patent protection for technology and products, allowing competitors to develop similar products.
• Dependence on licensors to maintain and enforce intellectual property rights, with limited control over their efforts.
• Risk of costly and time-consuming litigation for infringement of third-party intellectual property rights or to enforce own rights.
• Control by Fortress Biotech, Inc. (Fortress) through a voting majority, potentially leading to conflicts of interest and dilution of other stockholders.
• Potential involvement in securities class action litigation, diverting management attention and harming business.
• Volatility in the market price for common stock, with risk of significant future decline.
• Vulnerability to computer system failures, cyber-attacks, or deficiencies in cybersecurity, potentially damaging reputation and business.
• Business growth subject to economic and geopolitical conditions, including inflation, recession, and international conflicts.
• Inability to attract and retain key personnel, hindering effective business management.
• Risk of employee, consultant, or third-party misconduct, including noncompliance with regulatory standards or improper use of confidential information.
• Risk of delisting from Nasdaq if compliance with continued listing rules cannot be maintained.

Future Outlook

The company expects to continue incurring substantial operating losses for the foreseeable future and may never become profitable, with its continuation as a going concern dependent on raising additional capital. It plans to pursue investigator-sponsored single-institution clinical trials for MB-109 (combination of MB-101 and MB-108) and MB-106 (for autoimmune diseases) in the first quarter of 2026. The company is evaluating the impact of the newly signed 'One Big Beautiful Bill Act' (OBBBA) on its financial statements and operations.

Management Comments

• "We are a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers and autoimmune diseases."
• "We expect to incur substantial expenses for the foreseeable future relating to research, development and commercialization of our potential products. However, there can be no assurance that we will be successful in securing additional resources when needed, on terms acceptable to us, if at all. Therefore, there exists substantial doubt about our ability to continue as a going concern."
• "Because cell processing for MB-101 will revert back to COH... we believe that it is reasonable to assume that the FDA will not require a lead-in cohort... Should this, indeed, be the case, the first patient enrolled will receive combination therapy, which will represent a considerable savings of time and money as well as afford the potential benefit of both therapies to every patient treated on study."
• "We are in planning stages for a proof-of-concept investigator-sponsored clinical trial and actively evaluating potential indications in which MB-106 may be most effective and serve a patient population with high unmet need with a potential trial initiation in the first quarter of 2026."
• "We intend to use the net proceeds from the offering for working capital and general corporate purposes."

Industry Context

Mustang Bio operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on cutting-edge CAR T and oncolytic virus therapies for oncology and autoimmune diseases. This sector is characterized by long development timelines, high R&D costs, significant regulatory hurdles, and a high risk of clinical trial failures. The company's strategic shift to reduce operational costs and rely more on investigator-sponsored trials reflects a common challenge for early-stage biotechs in managing cash burn while advancing promising, albeit unproven, therapies. The receipt of Orphan Drug and RMAT designations is a positive sign within this context, as these designations aim to accelerate development and provide market incentives for therapies addressing rare or serious conditions with unmet needs.

Comparison to Industry Standards

• Direct comparisons to specific comparable companies, projects, or results are not provided within the filing.
• Generally, clinical-stage biopharmaceutical companies like Mustang Bio typically incur significant operating losses and negative cash flows due to extensive research and development expenses, a common characteristic before potential product commercialization.
• The company's accumulated deficit of $397.6 million is typical for a biotech company that has been in operation for several years without a commercialized product, reflecting the substantial investment required in drug development.
• The reliance on equity and debt financings, as well as the presence of a 'going concern' warning, is a frequent occurrence for early-stage biotechs that have not yet achieved profitability or consistent revenue streams from product sales.
• The strategic decision to reduce workforce and outsource manufacturing/clinical trial activities is a common industry practice for smaller biotechs to conserve capital and leverage external expertise, especially when facing financial constraints.

Corporate Governance

Related Party Transactions

• Mustang Bio is a majority-controlled subsidiary of Fortress Biotech, Inc. (Fortress).
• Under a Management Services Agreement with Fortress, the company recorded expenses of $0.1 million for Q2 2025 and $0.3 million for H1 2025.
• Pursuant to the Second Amended and Restated Founders Agreement, Fortress receives a grant of shares equal to 2.5% of the gross amount of any equity or debt financing. In H1 2025, 67,806 shares were issued to Fortress, resulting in a $0.2 million expense.
• An Annual Stock Dividend of 69,046 common shares was issued to Fortress on January 1, 2025, representing 2.5% of the fully-diluted outstanding equity.
• Fortress pays for certain expenses on behalf of Mustang Bio in the normal course of business.
• Mustang Bio moved its headquarters to office space leased by Fortress following the termination of its own facility lease, with Fortress allocating a portion of its rent and office costs to Mustang Bio monthly.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing and future equity financings, as well as potential loss of investment due to the 'going concern' uncertainty. The reverse stock split reduced the number of shares outstanding.
• **Employees**: Experienced a significant workforce reduction in 2024 as part of cost-cutting measures, impacting job security.
• **Patients**: Potential beneficiaries of the company's CAR T and oncolytic virus therapies for difficult-to-treat cancers and autoimmune diseases, with Orphan Drug and RMAT designations indicating high unmet medical needs.
• **Creditors**: May face risks if the company is unable to secure additional funding and continue as a going concern, potentially impacting the recoverability of liabilities.
• **Suppliers/Partners**: Continued reliance on third-party CROs, CMOs, and research institutions (City of Hope, Fred Hutch, Nationwide, UAB) for development and manufacturing, indicating ongoing business relationships but also potential for contract modifications or terminations due to financial constraints.

Next Steps

• Continue pursuing additional cash resources primarily through public or private equity financings.
• Explore initiating an investigator-sponsored single-institution study for MB-109 (combination of MB-101 and MB-108) at City of Hope in the first quarter of 2026.
• Explore initiating a Phase 1 trial for MB-106 in autoimmune diseases as an investigator-sponsored single-institution study at Fred Hutch in the first quarter of 2026.
• Evaluate the impact of the 'One Big Beautiful Bill Act' (OBBBA) on financial statements and operations.

Key Dates

Recommendation

While Mustang Bio has demonstrated significant progress in reducing its net losses and increasing its cash position through strategic cost-cutting and successful capital raises, the explicit 'substantial doubt about going concern' remains a critical risk. The company's product candidates are still in early clinical stages, with no revenue generation expected in the foreseeable future. The recent capital infusion provides a temporary lifeline, but long-term viability hinges on further successful financing and positive clinical trial outcomes. Given the high-risk, high-reward nature of clinical-stage biotech, coupled with the ongoing financial uncertainties, a 'hold' recommendation is appropriate for existing investors who are comfortable with high risk and believe in the long-term potential of the pipeline, while new investors should exercise extreme caution due to the significant going concern risk.

Keywords

Biopharmaceutical, CAR T Therapy, Oncolytic Virus, Cancer Treatment, Autoimmune Disease, Clinical Stage, Glioblastoma, Astrocytoma, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Orphan Drug Designation, RMAT Designation, SEC Filing, 10-Q, Biotech, Fortress Biotech